Actively Recruiting
Real-World Use of Lenacapavir for HIV Prevention An Observational Study on PrEP Persistence and Patterns in the United States
Led by Gilead Sciences · Updated on 2026-10-21
3000
Participants Needed
44
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are gathering real-world information on the use of lenacapavir LEN, YEZTUGO, YTG as a pre-exposure prophylaxis PrEP to prevent HIV infection in various clinical settings across the United States. The study aims to understand how LEN is started, used, and stopped during routine care and to evaluate how well participants continue using LEN PrEP over time. The main goal is to assess how many participants remain on LEN PrEP at 52 weeks. Participants may choose LEN PrEP through subcutaneous injection or other PrEP options including oral tablets emtricitabinetenofovir disoproxil fumarate or emtricitabinetenofovir alafenamide or intramuscular injections cabotegravir. The study observes participants who select LEN PrEP at enrollment or later and those who choose other PrEP methods or no PrEP. LEN is given via subcutaneous injection, and other drugs are taken orally or by intramuscular injection, depending on the option selected. Participants are followed to track their PrEP use, including how long they continue treatment, interruptions, switching between PrEP types, and coverage days protected by PrEP. The study collects data at enrollment and at weeks 26, 52, 78, and 104. Researchers evaluate persistence on LEN PrEP at week 52 as the primary measure. This observational study does not assign treatments but monitors real-life use of these prevention options over up to two years.
CONDITIONS
Brief Title
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Research Team
G
Gilead Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here